{
    "Trade/Device Name(s)": [
        "ARCHITECT 2nd Generation Testosterone",
        "ARCHITECT 2nd Generation Testosterone Calibrators",
        "ARCHITECT 2nd Generation Testosterone Controls"
    ],
    "Submitter Information": "Abbott Laboratories Diagnostics Division",
    "510(k) Number": "k120009",
    "Predicate Device Reference 510(k) Number(s)": [
        "k093421"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "July 27, 2012",
    "Summary Letter Received Date": "July 30, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.1680",
        "21CFR862.1150",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Testosterone test system",
        "Calibrator",
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube, glass",
        "Serum separator tube, plastic",
        "Serum separator II Advance",
        "Dipotassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT i System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT 2nd Generation Testosterone assay, calibrators, and controls for quantitation of testosterone in human serum and plasma using chemiluminescent microparticle immunoassay.",
    "Indications for Use Summary": "Quantitative determination of testosterone in human serum and plasma for diagnosis and treatment of disorders involving male sex hormones including hypogonadism, delayed or precocious puberty, impotence in males, and in females, hirsutism and virilization due to tumors, polycystic ovaries, and adrenogenital syndromes.",
    "fda_folder": "Clinical Chemistry"
}